Vector

向量

• 批准号: 7458728
• 负责人: KENNETH CORNETTA
• 金额: $ 15.98万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7458728
• 关键词: Adenovirus Vector; Antigens; Area; Attenuated; Basic Science; Biological Assay; Blood; Blood Cells; Bone Marrow Transplantation; Budgets; CSF3 gene; Cancer Biology; Cell Line; Cell physiology; Cells; Certification; Characteristics; Charge; Chimerism; Chronic; Chronic Granulomatous Disease; Clinical; Clinical Research; Clinical Trials; Clonal Evolution; Collaborations; Condition; Contracts; Core Facility; DNA; Detection; Development; Diagnostic; Diagnostic Services; Disease; Disease model; Doctor of Medicine; Doctor of Philosophy; Documentation; Dose; Enrollment; Enzyme-Linked Immunosorbent Assay; Enzymes; Equipment; Evaluation; Excision; Facility Construction Funding Category; Fanconi' s Anemia; Filtration; Funding; Funding Agency; Funding Mechanisms; Future; Gagging; Gene Transfer; Generations; Genes; Genetic; Germ Cells; Germany; Gibbon Ape Leukemia Virus; Glycoproteins; Goals; Grant; Granulomatous; Green Fluorescent Proteins; HIV; HIV-1; HIV-1 Reverse Transcriptase; Hela Cells; Hematological Disease; Hematopoietic; Hematopoietic stem cells; Host Defense; Human; Human Resources; Indiana; Indiana University Cancer Center; Industry; Institution; Intention; Iron binding capacity measurement; Journals; Laboratories; Laboratory Research; Lentivirus Vector; Letters; Link; Low Dose Radiation; MFG; Manuscripts; Medical; Medical Libraries; Methods; Modeling; Modification; Molecular; Mus; Mycoplasma; NADPH Oxidase; NIH Grants and Contracts; Nature; Neoplasms; Numbers; PERT; Patients; Pharmaceutical Preparations; Phase; Pik-off; Plasmid Cloning Vector; Plasmids; Polymerase Chain Reaction; Positioning Attribute; Postdoctoral Fellow; Preclinical Testing; Preparation; Principal Investigator; Procedures; Process; Production; Productivity; Protocols documentation; Publications; Published Comment; Quality Control; R7 Virus; RNA marker; RNA-Directed DNA Polymerase; Range; Reaction; Reagent; Recombinants; Recording of previous events; Replacement Therapy; Reporting; Research; Research Activity; Research Ethics Committees; Research Personnel; Research Project Grants; Resources; Retroviral Vector; Retroviridae; Risk; Rivers; Running; Safety; Sampling; Science; Screening procedure; Semliki forest virus; Series; Services; Signal Transduction; Source; Southern Blotting; Specialist; Spumavirus; Standards of Weights and Measures; Stem cells; Sterility; Students; Subfamily lentivirinae; Surface; System; T-Lymphocyte; TNFRSF5 gene; Technology; Testing; Therapeutic Studies; Time; Title; Training; Transduction Gene; Transfection; Transfer Agreement; Transplantation; Umbilical Cord Blood; United States Food and Drug Administration; United States National Institutes of Health; Universities; Urticaria; Validation; Vesicular stomatitis Indiana virus; Viral; Viral Vector; Virus; Washington; Work; Xenograft Model; Yang; anticancer research; base; benzonase; cancer research center director; cell bank; cell type; conditioning; congenic; cost; design; experience; gene replacement; gene therapy; gene therapy clinical trial; gene transfer vector; hydroxy-aluminum polymer; improved; in vivo; interest; man; peripheral blood; plasmid DNA; pol genes; pre-clinical; programs; promoter; quality assurance; reconstitution; response; retroviral-mediated; success; tissue culture; tool; transduction efficiency; tumor; vector; virology